Full article >>> patent expiration in the coming years including Zocor, Lipitor and others, and when this happens, you will see 80% or more of the revenue disappear within 12-24 months months. Imagine losing $10 billion in sales and profits that quickly?
For Big Pharma, it is all about acquiring other products or companies with products to survive. As a result M&A and licensing now takes up a lot of Big......
Full article >>> ing that three of the top 10 deals were Japanese companies buying other Japanese companies showing continued consolidation of this market. The amazing thing is that up to a year or two ago, M&A was not part of Japanese culture, but in order to survive Japanese companies have adapted. No major mega-mergers took place, but some significant acquisitions of biotech companies and generic companies took......
Full article >>> 90%, is slowing down to perhaps its lowest growth in years. In fact, all of the other regions in the world outpaced the U.S. with rapid growth taking place in Latin America and Asia. Nevertheless, the sheer size of the U.S. market (and pricing and profits) drives M&A activity as companies look to establish a better regional foothold. As a result, M&A activity will continue pressured by:
Full article >>>
Source:wistechnology.com By Michael Rosen 05/22/06
Related biology technology :
1. Third Wave reports clinical growth, continued loss
2. Electronic Tele-Communications reports continued challenges
3. The DIG System Nonradioactive Automated High-Throughput In Situ Hybridization: a Powerful Tool for Functional Genomics Research
4. Quantitation of the Protein MIA as a Marker for Chondrocytes in Research Samples
5. Control Your siRNA Research
6. Getting Started with MicroRNA Research
7. Monitoring Microbial Populations Using Real-Time qPCR on the MJ Research Opticon 2 System
8. Proteomics in Bladder Cancer Research: Protein Profiling of Bladder Squamous Cell Carcinomas, Rev C
9. Research Organics
10. A Robust LC/MS/MS Method for the Quantitation of Very Long Chain Fatty Acids for Research into the Characterization of Peroxisomal Disorders
11. A new LC/MS/MS Research Method for Rapid Quantitation of Five Immunosuppressant Drugs, including Mycophenolic Acid (MPA)
(Date:2/21/2017)... ... February 21, 2017 , ... Cancer ... Heritage has joined its executive team to lead the development and commercialization of ... to help improve the diagnosis and treatment of cancer. The CIDT addresses the ...
(Date:2/21/2017)... ... 21, 2017 , ... Creation Technologies, a private company and ... manufacturers (OEMs) , today announced it has received the ‘Highest Overall Customer Rating’ ... its category of electronics manufacturing services (EMS) providers with annual revenues over $500 ...
(Date:2/21/2017)... -- Scientists From Two Companies to Accelerate ... ... STEER, creator of advanced materials platform technologies that ... plastics, pharmaceuticals, food and nutraceuticals, biomaterials and biorefining, today announced ... technology company, on creating co-rotating twin screw extruder technology ...
(Date:2/20/2017)... 2017 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) announced today that ... Fabrice Orecchioni, the company,s COO, has been named President, effective immediately. ... four years, Fabrice has overseen the construction, start-up and operation of ... management of the Mitsui JV. Fabrice has also been extensively involved ... ...Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017 TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/25/2017)... NEW YORK , Jan. 25, 2017 /PRNewswire/ ... and Access Management (IAM) lifecycle is comprised of ... infrastructure for the purpose of maintaining digital identities ... enterprise resources and applications. There are significant number ... compliance from time to time by optimizing processes ...Breaking Biology News(10 mins):